Table 2 Baseline characteristics of papillary thyroid carcinoma patients with wildtype genotype of TERT promoter
Characteristic | No. (%) (Total = 120) |
|---|---|
Age at diagnosis (yr) | Â |
 < 55 | 104 (86.7%) |
 ≥ 55 | 16 (13.3%) |
 Median(range) | 38 (21–73) |
Sex | Â |
 Female | 93 (77.5%) |
 Male | 27 (22.5%) |
Histologic variant | Â |
 Classic | 100 (83.3%) |
 Follicular | 7 (5.8%) |
 Tall cell | 5 (4.2%) |
 Diffuse sclerosing | 5 (4.2%) |
 Solid | 3 (2.5%) |
Multifocality | Â |
 Yes | 37 (30.8%) |
 No | 83 (69.2%) |
Vascular invasion | Â |
 Yes | 7 (5.8%) |
 No | 113 (94.2%) |
Extrathyroidal extension | Â |
 Absent | 82 (68.3%) |
 Minimal | 36 (30%) |
 Gross (T3b) | 2 (1.7%) |
 Gross (T4) | 0 (0%) |
Hashimoto’s thyroiditis |  |
 Yes | 24 (20%) |
 No | 96 (80%) |
Tumor size (cm) | Â |
 ≤ 1 | 85 (70.8%) |
 > 1, ≤ 2 | 32 (26.7%) |
 > 2, ≤ 4 | 3 (2.5%) |
 > 4 | 0 (%) |
Pathologic T category | Â |
 T1 | 116 (96.7%) |
 T2 | 3 (2.5%) |
 T3 | 1 (0.8%) |
 T4 | 0 (%) |
Pathologic N category | Â |
 N0 | 59 (49.2%) |
 N1 | 61 (50.8%) |
ATA recurrence risk | Â |
 Low | 65 (54.2%) |
 Intermediate | 48 (40%) |
 High | 7 (5.8%) |
AJCC staging | Â |
 I | 111 (92%) |
 II | 9 (8%) |
 III | 0 (0%) |
 IV | 0 (0%) |
BRAF V600E mutation | Â |
 Present | 104 (86.7%) |
 None | 16 (13.3%) |